צמיחת מכירות משנה לשנה ב-12 החודשים האחרונים: Tempus AI, Inc (TEM)

Tempus AI, Inc (TEM) integrates artificial intelligence with precision medicine to combat cancer. Year-over-year revenue growth over the trailing twelve months (TTM) confirms this potential, and the value of 36.30 shows the most recent figure. Visionary management is aggressively expanding DNA data sets despite current losses. A high barrier to entry is ensured by a unique AI platform and the network effect.

For Tempus AI, Inc (TEM), the rapid monetization of unique oncology datasets demanded by pharma behemoths is directly reflected in the expansion rate of operating income. By analyzing revenue volatility compared to the same period last year over the TTM, an investor can observe a rolling annual sales growth that offsets quarterly lags and demonstrates the real-time scaling dynamics of the business.